Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors
Open Access
- 15 May 2018
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 20 (12) , 1522-1528
Abstract
Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should differ from other kind of tumors.Keywords
Funding Information
- Novartis
This publication has 30 references indexed in Scilit:
- Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRICancer Imaging, 2013
- Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumourEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine TumorPancreas, 2010
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide TherapyJournal of Nuclear Medicine, 2009
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and DocumentationNeuroendocrinology, 2009
- The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumorsEndocrine-Related Cancer, 2009
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase InhibitorClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Responding to 4 gastrointestinal complications in cancer patientsNursing, 2008
- Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDGCancer, 2008